Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up
 to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04
 or DRM04-HH05 studies.
Safety will be assessed through adverse events, blood and urine laboratory tests, physical
 examination, pulse and blood pressure. Local skin reactions will be assessed including
 burning/stinging, pruritus, edema, erythema, dryness and scaling.
Inclusion Criteria:

 -  Completed Day 28 of either the DRM04-HH04 or DRM04-HH05 study with at least 80%
 treatment compliance

 -  Male or females

 Exclusion Criteria:

 -  Subject has a clinically significant abnormality on physical exam, vital signs or ECG
 at the Week 4 visit of DRM04-HH04 or DRM04-HH05 study that would make further
 treatment with glycopyrronium contraindicated

 -  Male with a history of urinary retention requiring catheterization due to prostatic
 hypertrophy or severe obstructive symptoms of prostatic hypertrophy

 -  Any other condition which, in the judgement of the Investigator, would put the subject
 at unacceptable risk for participation in the study